Eidos Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 57.21 | -100% | -20.06 | -100% |
| P/S |
|
36595.5 | 33.44 | 109350.37% |
|
|
| P/BV |
|
38.7 | 4.65 | 732.69% |
|
|
| P/FCF |
|
-55.23 | 42.56 | -229.77% |
|
|
| Ev/Ebitda |
|
-49.6 | -17.68 | 180.6% |
|
|
| Ev/S |
|
0.0381 | 22.52 | -99.83% |
|
|
| Ev/FCF |
|
-56.28 | 47.58 | -218.27% |
|
|
| E/P |
|
-0.0213 | 0.0188 | -213.28% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-0.0787 | -13.3 | -99.41% | -0.0394 | +100% |
| ROE |
|
-70.31 | 9.69 | -825.57% |
|
|
| ROA |
|
-59.27 | 0.2896 | -20565.88% |
|
|
| ROIC |
|
-62.91 | 7.63 | -924.04% |
|
|
| ROS |
|
-0.0795 | -25.08 | -99.68% |
|
|
| ROCE |
|
0 | 14.58 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.2 | -3.62 | -94.48% | -0.2 | -0% |
| Nеt Debt/Ebitda |
|
0 | -4.05 | -100% |
|
|
| Debt/Ratio |
|
0 | 0.1841 | -100% |
|
|
| Debt/Equity |
|
0 | 1.6 | -100% |
|
|
| Debt/Net Income |
|
-0.198 | 0.9168 | -121.6% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5448 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.7368 | -100% | ||
| DSI |
|
0 | 0.2387 | -100% |
|
|
| Average dividend growth |
|
0 | 1.55 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4954 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.64 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5448 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
470270.37 | 31.71 | 1482934.91% | ||
| Growth impulse Ebitda in 5 years |
|
0 | -23.28 | -100% | ||
| Growth impulse Net Income in 5 years |
|
3233.33 | -61.56 | -5352.32% | ||
| Growth impulse FCF in 5 years |
|
1500 | -26 | -5869.23% | ||
| Growth impulse EPS in 5 years |
|
1938.46 | -63.63 | -3146.46% |
IP Score
4/10
